Listed

Castle Biosciences Inc

CSTLNasdaqCIK 1447362HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$103.5mRevenue, Q2 FY2026, three months to 2026-06-30$103.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Jul 30, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$103.5mRevenue, Q2 FY2026, three months to 2026-06-30$103.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figure+20.1% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−3.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Revenue: $103.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figure+2.0 pts on a year earlier
  • Net margin−2.0%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Revenue: $103.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figure−7.2 pts on a year earlier
  • Diluted EPS−$0.07Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figureSign changed from a year earlier
  • Free cash flow$6.6mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $15.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001628280-26-051052. Derived: 6-month figure less the 3-month figure.Capital expenditure: $8.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0001628280-26-051052. Derived: 6-month figure less the 3-month figure.Report this figure−43.3% on a year earlier

Last eight quarters

Full statements
Revenue$103.5mOperating margin −3.0%
Diluted EPS−$0.07, Q2 FY2026
Free cash flow$6.6m, Q2 FY2026
Castle Biosciences Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m85.8Revenue, Q3 FY2024, three months to 2024-09-30$85.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Report this figure86.3Revenue, Q4 FY2024, three months to 2024-12-31$86.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Report this figure88.0Revenue, Q1 FY2025, three months to 2025-03-31$88.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Report this figure86.2Revenue, Q2 FY2025, three months to 2025-06-30$86.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figure83.0Revenue, Q3 FY2025, three months to 2025-09-30$83.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Report this figure87.0Revenue, Q4 FY2025, three months to 2025-12-31$87.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Report this figure83.7Revenue, Q1 FY2026, three months to 2026-03-31$83.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Report this figure104Revenue, Q2 FY2026, three months to 2026-06-30$103.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%5.9%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $5.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Revenue: $85.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Report this figure4.7%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Revenue: $86.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Report this figure(31.7%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$27.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Revenue: $88.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Report this figure(4.9%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$4.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Revenue: $86.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figure(8.2%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$6.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Revenue: $83.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Report this figure(4.4%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$3.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Revenue: $87.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Report this figure(22.0%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$18.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Revenue: $83.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Report this figure(3.0%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Revenue: $103.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figure
Net margin%2.6%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Revenue: $85.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Report this figure11.1%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $9.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Revenue: $86.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Report this figure(29.4%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$25.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Revenue: $88.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Report this figure5.2%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Revenue: $86.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figure(0.6%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$501.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Revenue: $83.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Report this figure(2.7%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Revenue: $87.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Report this figure(17.4%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$14.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Revenue: $83.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Report this figure(2.0%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Revenue: $103.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figure
Diluted EPS$ per share0.08Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Report this figurenot reported (Diluted EPS not reported)(0.90)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Report this figure0.15Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figure(0.02)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0001628280-25-048254.Report this figurenot reported (Diluted EPS not reported)(0.49)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Report this figure(0.07)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001628280-26-051052.Report this figure
Free cash flow$m17.0Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $23.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0001628280-25-048254. Derived: 9-month figure less the 6-month figure.Capital expenditure: $6.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-03, accession 0001628280-25-048254. Derived: 9-month figure less the 6-month figure.Report this figure16.8Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $24.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Capital expenditure: $7.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Report this figure(10.8)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$6.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Capital expenditure: $4.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Report this figure11.6Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $20.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001628280-26-051052. Derived: 6-month figure less the 3-month figure.Capital expenditure: $9.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0001628280-26-051052. Derived: 6-month figure less the 3-month figure.Report this figure7.8Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $22.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0001628280-25-048254. Derived: 9-month figure less the 6-month figure.Capital expenditure: $14.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-03, accession 0001628280-25-048254. Derived: 9-month figure less the 6-month figure.Report this figure19.7Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $26.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Capital expenditure: $7.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012272. Derived: 12-month figure less the 9-month figure.Report this figure(34.6)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$22.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Capital expenditure: $12.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001628280-26-031263.Report this figure6.6Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $15.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001628280-26-051052. Derived: 6-month figure less the 3-month figure.Capital expenditure: $8.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0001628280-26-051052. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$344.2mOperating margin −12.4%
Diluted EPS−$0.83, FY2025
Free cash flow$28.3m, FY2025
Castle Biosciences Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m94.1Revenue, FY2021, twelve months to 2021-12-31$94.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-02-28, accession 0001447362-23-000038.Report this figure137Revenue, FY2022, twelve months to 2022-12-31$137.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001447362-25-000031.Report this figure220Revenue, FY2023, twelve months to 2023-12-31$219.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure332Revenue, FY2024, twelve months to 2024-12-31$332.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure344Revenue, FY2025, twelve months to 2025-12-31$344.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(42.6%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$40.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-02-28, accession 0001447362-23-000038.Revenue: $94.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-02-28, accession 0001447362-23-000038.Report this figure(53.2%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$72.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0001447362-25-000031.Revenue: $137.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001447362-25-000031.Report this figure(30.9%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$68.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012272.Revenue: $219.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure2.6%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $8.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012272.Revenue: $332.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure(12.4%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$42.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012272.Revenue: $344.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure
Net margin%(33.3%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$31.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-02-28, accession 0001447362-23-000038.Revenue: $94.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-02-28, accession 0001447362-23-000038.Report this figure(49.0%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$67.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0001447362-25-000031.Revenue: $137.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001447362-25-000031.Report this figure(26.1%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$57.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012272.Revenue: $219.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure5.5%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $18.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012272.Revenue: $332.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure(7.0%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$24.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012272.Revenue: $344.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure
Diluted EPS$ per share(1.24)Diluted EPS, FY2021, twelve months to 2021-12-31−$1.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-02-28, accession 0001447362-23-000038.Report this figure(2.58)Diluted EPS, FY2022, twelve months to 2022-12-31−$2.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-27, accession 0001447362-25-000031.Report this figure(2.14)Diluted EPS, FY2023, twelve months to 2023-12-31−$2.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure0.62Diluted EPS, FY2024, twelve months to 2024-12-31$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure(0.83)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure
Free cash flow$m(22.5)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$19.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-02-28, accession 0001447362-23-000038.Capital expenditure: $3.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-02-28, accession 0001447362-23-000038.Report this figure(47.3)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$41.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0001447362-25-000031.Capital expenditure: $5.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0001447362-25-000031.Report this figure(19.2)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012272.Capital expenditure: $13.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure36.5Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $64.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012272.Capital expenditure: $28.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure28.3Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $64.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012272.Capital expenditure: $36.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012272.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

By month, by reported value, last 24 monthsPurchases $0Sales $108.8k
Castle Biosciences Inc, open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2026-10-26Juvenal Tobin WChief Commercial Officer, Officer Sale3,288$33.08$108.8kForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Castle Biosciences Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$78.5m3,291,963Added+309,017
RTW INVESTMENTS, LP2026-06-30$66.3m2,778,335Added+20,000
PRINCIPAL FINANCIAL GROUP INC2026-06-30$41.2m1,726,648Reduced−43,229
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$29.3m1,226,497Added+48,975
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$20.1m840,785Reduced−20,986
Allianz Asset Management GmbH2026-06-30$19.9m811,324Unchanged
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC2026-06-30$19.7m824,872Reduced−115,813
STATE STREET CORP2026-06-30$19.6m822,079Added+53,000
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$19.0m795,912Added+67,812
MACKENZIE FINANCIAL CORP2026-06-30$18.9m793,507Added+719,396

Recent filings

All 882 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Castle Biosciences Inc, recent filings
FiledFormWhat it isAccession number
2026-07-3016:09 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-051052
2026-07-3016:06 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-051045
2026-05-2916:14 ET8-K5.07 Shareholder vote results0001628280-26-039189
2026-05-0616:09 ET10-QQuarterly reportPeriod 2026-03-310001628280-26-031263
2026-05-0616:07 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-031255
2026-04-0810:13 ETDEF 14AProxy statementPeriod 2026-05-280001628280-26-024166
2026-02-2616:09 ET10-KAnnual reportPeriod 2025-12-310001628280-26-012272
2026-02-2616:07 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-012263
2026-01-1309:43 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-001909
2025-11-0316:16 ET10-QQuarterly reportPeriod 2025-09-300001628280-25-048254

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1447362
Tickers
CSTL
Exchange
Nasdaq
SIC code
8071 Services-Medical Laboratories
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 10:33 ET. Listed shows no prices and gives no investment advice.